ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India - An Update (2025).
作者信息
Madhu Sri Venkata, Kapoor Nitin, Das Sambit, Raizada Nishant, Kalra Sanjay
机构信息
Department of Endocrinology, Centre for Diabetes, Endocrinology and Metabolism, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India.
Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India.
出版信息
Indian J Endocrinol Metab. 2025 Jul-Aug;29(4):355-365. doi: 10.4103/ijem.ijem_680_25. Epub 2025 Aug 26.
Abstract
摘要
相似文献
1
ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India - An Update (2025).印度肥胖评估与管理的ESI临床实践指南 - 2025年更新版
Indian J Endocrinol Metab. 2025 Jul-Aug;29(4):355-365. doi: 10.4103/ijem.ijem_680_25. Epub 2025 Aug 26.
2
Content and quality of clinical practice guidelines for the management of type 2 diabetes in India: A systematic review.印度 2 型糖尿病管理临床实践指南的内容和质量：系统评价。
Endocrinol Diabetes Metab. 2023 Mar;6(2):e405. doi: 10.1002/edm2.405. Epub 2023 Jan 16.
3
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update.成人肥胖管理的药物治疗：2025年临床实践指南更新
CMAJ. 2025 Aug 10;197(27):E797-E809. doi: 10.1503/cmaj.250502.
4
Executive Summary of the Clinical Practice Guideline on Adult Sinusitis Update.《成人鼻窦炎更新临床实践指南》执行摘要
Otolaryngol Head Neck Surg. 2025 Aug;173(2):299-316. doi: 10.1002/ohn.1342.
5
Preoperative cardiac evaluation in elective non-cardiac surgery in India: Routine ECG, echocardiography, and angiography are not mandatory.印度择期非心脏手术的术前心脏评估：常规心电图、超声心动图和血管造影并非必需。
J Hand Microsurg. 2025 Jun 25;17(5):100321. doi: 10.1016/j.jham.2025.100321. eCollection 2025 Sep.
6
Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.临床指南和支付方政策对慢性下腰痛融合治疗的影响。
Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4.
7
Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia.维生素 D 辅助抗生素治疗儿童急性肺炎。
Cochrane Database Syst Rev. 2023 Jan 12;1(1):CD011597. doi: 10.1002/14651858.CD011597.pub3.
8
Discrepancies Between Recommendations in Evidence-Based Guidelines for the Management of Obesity in Adolescents and Adults: An Evidence Map.青少年和成人肥胖管理的循证指南中的建议差异：证据图谱
Obes Rev. 2025 Oct;26(10):e13945. doi: 10.1111/obr.13945. Epub 2025 May 27.
9
Clinical Practice Updates: AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.临床实践更新：美国胃肠病学会关于可弯曲性埃勒斯-当洛综合征的胃肠道表现及自主神经或免疫功能障碍的临床实践更新：专家综述
Clin Gastroenterol Hepatol. 2025 May 19. doi: 10.1016/j.cgh.2025.02.015.
10
Position statement and guidelines about Endoscopic Sleeve Gastroplasty (ESG) also known as "Endo-sleeve".关于内镜下袖状胃成形术（ESG，也称为“内镜袖套术”）的立场声明和指南。
J Visc Surg. 2025 Feb;162(1):71-78. doi: 10.1016/j.jviscsurg.2024.12.003. Epub 2025 Jan 9.
本文引用的文献
1
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.卡格列净与司美格鲁肽联合用于超重或肥胖成人患者。
N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502081.
2
Definition and diagnostic criteria of clinical obesity.临床肥胖的定义和诊断标准。
Lancet Diabetes Endocrinol. 2025 Mar;13(3):221-262. doi: 10.1016/S2213-8587(24)00316-4. Epub 2025 Jan 14.
3
Tirzepatide for overweight and obesity management.替尔泊肽用于超重和肥胖管理。
Expert Opin Pharmacother. 2025 Jan;26(1):31-49. doi: 10.1080/14656566.2024.2436595. Epub 2024 Dec 4.
4
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss.健康与幸福指导辅助GLP-1诱导的体重减轻。
Am J Lifestyle Med. 2024 Nov 19:15598276241302273. doi: 10.1177/15598276241302273.
5
Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: A qualitative research study with registered dietitians.优化用于体重管理的胰高糖素样肽-1（GLP-1）药物治疗中的营养、饮食及生活方式沟通：一项对注册营养师的定性研究
Obes Pillars. 2024 Oct 13;12:100143. doi: 10.1016/j.obpill.2024.100143. eCollection 2024 Dec.
6
Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.GLP-1 类似物艾塞那肽在成人 2 型糖尿病中的疗效和安全性：一项随机、双盲、安慰剂对照的 2 期临床试验。
Nat Commun. 2024 Sep 27;15(1):8408. doi: 10.1038/s41467-024-52353-y.
7
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.每周一次司美格鲁肽 2.4mg 用于超重或肥胖的主要为东亚人群的体重管理的疗效和安全性（STEP 7）：一项双盲、多中心、随机对照试验。
Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. doi: 10.1016/S2213-8587(23)00388-1. Epub 2024 Feb 5.
8
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.胰高血糖素和 GLP-1 受体双重激动剂索马鲁肽治疗肥胖症的随机、双盲、安慰剂对照、剂量探索 2 期临床试验。
Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. doi: 10.1016/S2213-8587(23)00356-X. Epub 2024 Feb 5.
9
Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.与安慰剂和开放标签司美格鲁肽相比，双重胰高血糖素/GLP-1受体激动剂司伏鲁肽对2型糖尿病患者糖化血红蛋白（HbA）和体重减轻的剂量反应效应：一项随机临床试验
Diabetologia. 2024 Mar;67(3):470-482. doi: 10.1007/s00125-023-06053-9. Epub 2023 Dec 14.
10
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
Zotero 插件